Docoh
Loading...

AMED Amedisys

News

Pro users get this 30m faster
Analyst Ratings For Amedisys
13 Oct 21
Analyst Ratings
Within the last quarter, Amedisys (NASDAQ:AMED) has observed the following analyst ratings:
Truist Securities Maintains Buy on Amedisys, Lowers Price Target to $190
13 Oct 21
News, Price Target, Analyst Ratings
Truist Securities analyst David Macdonald maintains Amedisys (NASDAQ:AMED) with a Buy and lowers the price target from $255 to $190.
What 9 Analyst Ratings Have To Say About Amedisys
27 Sep 21
Analyst Ratings
Amedisys (NASDAQ:AMED) has observed the following analyst ratings within the last quarter:
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2021
27 Sep 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
SVB Leerink Initiates Coverage On Amedisys with Market Perform Rating, Announces Price Target of $170
27 Sep 21
News, Price Target, Initiation, Analyst Ratings
SVB Leerink analyst Whit Mayo initiates coverage on Amedisys (NASDAQ:AMED) with a Market Perform rating and announces Price Target of $170.
Where Amedisys Stands With Analysts
24 Sep 21
Analyst Ratings
Within the last quarter, Amedisys (NASDAQ:AMED) has observed the following analyst ratings:
Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021
24 Sep 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
UBS Initiates Coverage On Amedisys with Sell Rating, Announces Price Target of $150
24 Sep 21
News, Price Target, Initiation, Analyst Ratings
UBS initiates coverage on Amedisys (NASDAQ:AMED) with a Sell rating and announces Price Target of $150.
Amedisys To Buy Regulatory Assets Allowing Co. To Establish Home Health Care Centers To Fully Service, Expand Charlotte, Raleigh, North Carolina Markets
20 Sep 21
M&A
Amedisys, Inc. (NASDAQ:AMED), a leading provider of quality home health, hospice and personal care, has signed a definitive agreement to acquire regulatory assets that allow the Company to establish home health care
Where Amedisys Stands With Analysts
10 Sep 21
Analyst Ratings
Within the last quarter, Amedisys (NASDAQ:AMED) has observed the following analyst ratings:
Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021
10 Sep 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Cowen & Co. Initiates Coverage On Amedisys with Market Perform Rating, Announces Price Target of $195
10 Sep 21
News, Price Target, Initiation, Analyst Ratings
Cowen & Co. analyst Gary Taylor initiates coverage on Amedisys (NASDAQ:AMED) with a Market Perform rating and announces Price Target of $195.
Analyst Ratings For Amedisys
31 Aug 21
Analyst Ratings
Over the past 3 months, 6 analysts have published their opinion on Amedisys (NASDAQ:AMED) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Stocks That Hit 52-Week Lows On Monday
23 Aug 21
News, Intraday Update, Markets, Movers, Trading Ideas
Before 10 a.m. ET on Monday, 29 stocks hit new 52-week lows.
What 6 Analyst Ratings Have To Say About Amedisys
21 Aug 21
Analyst Ratings
Within the last quarter, Amedisys (NASDAQ:AMED) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago
Return on Capital Employed Overview: Amedisys
20 Aug 21
Earnings
After pulling data from Benzinga Pro it seems like during Q2, Amedisys (NASDAQ:AMED) earned $78.14 million, a 13.49% increase from the preceding quarter. Amedisys also posted a total of $564.17 million in sales, a 5.03% increase since Q1.
Stocks That Hit 52-Week Lows On Thursday
19 Aug 21
News, Intraday Update, Markets, Movers, Trading Ideas
Thursday morning, 173 companies reached new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
12 Aug 21
News, Intraday Update, Markets, Movers, Trading Ideas
During Thursday's morning trading, 83 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
11 Aug 21
News, Intraday Update, Markets, Movers, Trading Ideas
On Wednesday morning, 67 companies achieved new lows for the year.
Credit Suisse Maintains Outperform on Amedisys, Lowers Price Target to $250
11 Aug 21
News, Price Target, Analyst Ratings
Credit Suisse maintains Amedisys (NASDAQ:AMED) with a Outperform and lowers the price target from $330 to $250.